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Abstract
Background: Regression of established tumors can be induced by adoptive immunotherapy with tumor draining
lymph node lymphocytes activated with bryostatin and ionomycin. We hypothesized that tumor regression is
mediated by a subset of the transferred T lymphocytes, which selectively infiltrate the tumor draining lymph nodes
and proliferate in vivo.
Results: Adoptive transfer of B/I activated tumor draining lymphocytes induces regression of advanced 4T1 tumors,
and depletion of CD8, but not CD4 T cells, abrogated tumor regression in mice. The predominant mediators of
tumor regression are CD8+ and derived from CD62L
- T cells. Transferred lymphocytes reached their peak
concentration (10.5%) in the spleen 3 days after adoptive transfer and then rapidly declined. Adoptively transferred
cells preferentially migrated to and/or proliferated in the tumor draining lymph nodes, peaking at day 5 (10.3%)
and remained up to day 28. CFSE-stained cells were seen in tumors, also peaking at day 5 (2.1%). Bryostatin and
ionomycin-activated cells proliferated vigorously in vivo, with 10 generations evident in the tumor draining lymph
nodes on day 3. CFSE-stained cells found in the tumor draining lymph nodes on day 3 were 30% CD8
+, 72% CD4
+,
95% CD44
+, and 39% CD69
+. Pre-treatment of recipient mice with cyclophosphamide dramatically increased the
number of interferon-gamma producing cells.
Conclusions: Adoptively transferred CD8+ CD62L
low T cells are the principal mediators of tumor regression, and
host T cells are not required. These cells infiltrate 4T1 tumors, track preferentially to tumor draining lymph nodes,
have an activated phenotype, and proliferate in vivo. Cyclophosphamide pre-treatment augments the anti-tumor
effect by increasing the proliferation of interferon-gamma producing cells in the adoptive host.
Background
Conventional therapies for cancer, including surgery,
radiation and chemotherapeutic agents, are often ineffec-
tive at controlling the growth and spread of tumors. The
immune system can potentially eliminate cancerous cells,
as demonstrated by studies of numerous animal models
and a few clinical trials [1,2]. In most cases, it is thought
that anti-tumor effects are mediated by cytotoxic T lym-
phocytes (CTL), which recognize MHC class I-peptide
complexes on the tumor cell surface [3]. Monoclonal
antibodies, cytokines, and pharmacological methods have
been used successfully in mouse models to activate lym-
phocytes isolated from tumors or tumor draining lymph
nodes (DLN), which can then be adoptively transferred
to tumor bearing hosts and cause regression of estab-
lished tumors [4-15]. Adoptive immunotherapy (AIT), or
the adoptive transfer of antigen-sensitized T cells acti-
vated and/or expanded in vitro continues to receive
attention [10] [16-23].
We have shown that in vitro treatment with bryostatin
and ionomycin (B/I) selectively activates antigen-sensitized
tumor draining lymph node (tDLN) lymphocytes [19-22].
Bryostatin 1 is a macrocyclic lactone derived from Bugula
neritina, a marine invertebrate. Bryostatin activates protein
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any medium, provided the original work is properly cited.kinase C [23-26] and ionomycin increases intracellular cal-
cium [27]. Together, these mimic signaling through the
CD3/TcR complex and lead to activation and proliferation
of T cells [24,27].
Previous research in our lab has shown that adoptive
transfer of B/I activated tumor draining lymphocytes
can cure subcutaneous tumors and visceral metastases
in murine hosts and establish long-term immunity,
without evidence of autoimmunity. In the 4T1 mam-
mary carcinoma model, we have shown that B/I selec-
tively activates CD62L
- or sensitized T cells and that the
anti-tumor activity resides in the CD62L
- fraction of
lymphocytes obtained from donor lymph nodes; only
the CD62L
- subset proliferates after B/I activation and
has anti-tumor activity [28]. CD62L or L-selectin is an
adhesion molecule important in T cell homing to lymph
nodes and is down-regulated after T cells are activated
and differentiate into their effector or effector memory
(TEM) phenotypes [29,30]. Thus, because of this selective
activation of antigen-sensitized T cells from the vacci-
nated donor mice, B/I stimulated DLN lymphocytes
have tumor antigen specific activity in vivo, despite the
non-specific stimulus used to promote their growth.
We hypothesized that B/I activated T cells mediate
tumor regression primarily by CD8
+ T cell mediated
functions and may establish T cell memory in the adop-
tive host by proliferating in vivo. B/I activated cells were
characterized prior to adoptive transfer, and the most
active subsets of cells identified by depletion or separa-
tion of phenotypically distinct subsets of T cells prior to
AIT. By AIT using CFSE-labeled cells, we were also able
to determine the trafficking patterns and measure the
in vivo proliferation of B/I-activated T cells in tumor-
bearing hosts.
Methods
Mice
Virus-free BALB/c mice (Charles River Laboratories,
Cambridge, MA) were used between 8 and 12 weeks of
age, caged in groups of 6 or fewer, and provided food
and water ad libitum. Nude athymic BALB/c mice
(National Cancer Institute, Bethesda, MD) were used to
produce hybridoma ascites. All guidelines of the Virginia
Commonwealth University Institutional Animal Care
and Use Committee, which conform to the American
Association for Accreditation of Laboratory Animal
Care and the U.S. Department of Agriculture recom-
mendations for the care and humane experimental use
of animals, were followed.
Tumor cell lines and Hybridomas
4T1 mammary tumor cell line was kindly provided by
Dr. Jane Tsai at the Michigan Cancer Foundation,
Detroit, Michigan. Cells were maintained in Dulbecco’s
Modified Essential Medium (DMEM) with 10% heat-
inactivated fetal calf serum (Hyclone, Logan, UT), 1 mM
sodium pyruvate, 100 U/ml penicillin and 100 μg/ml
streptomycin (Sigma, St. Louis MO) (modified DMEM).
Meth A sarcoma, an unrelated tumor cell line (ATCC,
Rockville, MD) was maintained in RPMI 1640 medium
with 10% heat-inactivated FCS, 1 mM sodium pyruvate,
0.1 mM nonessential amino acids, 2 mM L-glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin, 10 mM
Hepes buffer, and 5 × 10
-5 M 2-mercaptoethanol
(Sigma). Tumor cells were harvested for inoculation of
mice with 0.05% trypsin-EDTA (Fisher, Pittsburgh, PA).
Hybridomas (GK1.5 (anti-CD4), 2.43 (anti-CD8)) were
obtained from ATCC and grown in complete RPMI. All
cells were incubated in 250 ml T-flasks (PGC, Gaithers-
burg, MD) at 37°C in humidified air with 5% CO2.
Monoclonal Antibody production
Anti-CD4 monoclonal antibody (mAb) and anti-CD8
mAb were produced as ascites fluid from pristane-
primed nude mice injected with their respective
hybridomas.
Draining lymph node sensitization
Donor mice were vaccinated in the left hind footpad
with 1 × 10
6 4T1 cells. Ten days after footpad vaccina-
tion, popliteal tumor draining lymph nodes (tDLN) were
harvested under sterile conditions.
Lymphocyte activation and in vitro expansion
DLN’s were harvested and dispersed into a single cell sus-
pension in complete RPMI media at 1 × 10
6 cells/ml. The
cells were activated by incubation with 5 nM bryostatin 1
(provided by the National Cancer Institute, Bethesda, MD)
and 10 nM ionomycin (Calbiochem, San Diego, CA) (B/I),
and 80 U/ml of rIL-2 (Chiron, Emeryville, CA) at 37°C for
18 hours. Cells were washed three times with warm com-
plete RPMI and resuspended at 1-2 × 10
6 cells/ml with 40
U/ml of rIL-2. The cells were allowed to proliferate in cul-
ture for an additional 7 days and were split every 2-3 days
in order to maintain 1-2 × 10
6 cells/ml concentration.
Adoptive immunotherapy
Host mice were inoculated in the left flank with 2.5 ×
10
4 -5×1 0
4 4T1 cells (2.5 × 10
4 for 7-10 day tumors,
5×1 0
4 for 4 day tumors). One day prior to AIT, mice
were pretreated with cyclophosphamide (CYP),100 mg/
kg IP(Mead Johnson, Princeton, NJ). On day 4, 7 or 10,
the B/I activated and expanded DLN lymphocytes were
washed twice in serum free medium (RPMI 1640) and
injected intravenously (IV) in 0.5 ml into host mice. No
systemic cytokines were administered.
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Prior to adoptive immunotherapy, B/I activated DLN
lymphocytes were stained with 50 μMC F D A - S E( M o l e -
cular Probes, Eugene, OR) in PBS at a concentration of
75 million cells/ml for 15 minutes. Cells were washed
with warm media and incubated at 37°C for 30 minutes
to allow processing by intracellular proteases. CFSE-
stained lymphocytes were injected IV into CYP-treated
or untreated mice bearing 4T1 tumors.
Flow cytometry
Cells isolated from spleen, tumor, inguinal tDLN, and
cLN of control or treated mice at various time points
were stained with a panel of antibodies and analyzed by
dual color flow cytometry for CFSE and surface marker
expression on an ELITE Beckman Coulter flow cyt-
ometer. Fluorescently labeled Abs directed against the
following markers were obtained from Pharmingen (San
Diego, CA): Pan-DX5(DX5), CD4 (GK1.5), CD8 (53-6.7),
CD44 (IM7), CD62L (MEL-14), and CD69 (H1.2F3).
Appropriate isotype controls were used in all cases. Gen-
erations of proliferation detected by CFSE fluorescence
were analyzed using ModFit LT (Verity Software House,
Topsham, Maine) and acceptable fits were determined by
reduced Chi-Squared values.
In vitro T cell subset depletion experiments
For in vitro depletion studies, DLN were first incubated
with antibody (1:100) for 30 minutes, washed, and then
incubated with rabbit complement (C’) (Accurate Chemi-
cal) at 37°C for 30 minutes. The efficacy of the depletion
was tested by flow cytometry. To determine the CD62L
phenotype of the sensitized T cell precursors that were
activated by B/I to become anti-tumor effectors or of the
cells after B/I activation that mediated anti-tumor effects
in adoptive hosts, DLN cells before and/or after activation
with B/I were separated into CD62L
- and CD62L
+ subsets
using magnetic bead separation (EasySep, Stem Cell Tech-
nologies). Flow cytometry was used to verify fractionation.
Tumor measurements
In all AIT experiments, tumor growth was monitored
with biweekly measurements of perpendicular diameters.
Results are reported as the mean tumor area ± standard
error (SE). When the tumor area was greater than 100
mm
2 or if a mouse appeared ill, the animal was eutha-
nized by CO2 inhalation. Complete tumor regression
was defined as the absence of a measurable tumor on
three consecutive measurements.
Cytokine release assays
Interferon-g (IFN-g) release from tumor sensitized, fresh
or B/I activated and expanded lymphocytes in response
to stimulation with irradiated 4T1 and irradiated Meth A
for 24 hours was assayed using ELIspot assays from
Pharmingen (San Diego, CA).
Statistical analysis
Differences in tumor growth were assessed by analysis of
variance (ANOVA) and Tukey-Kramer honestly signifi-
cant difference test (Tukey’s HSD) using JMPIN software
(SAS Institute Inc., Cary, N.C.). In vivo experiments
included at least six mice per group and were repeated at
least twice. A p < 0.05 was used throughout to determine
significant differences.
Results
Adoptive transfer of tDLN activated by B/I and expanded
in vitro induces regression of 10 day 4T1 tumors
Host Balb/C mice with 4T1 tumors were untreated, trea-
ted with CYP on day 9, or treated with CYP followed on
d a y1 0b ya d o p t i v et r a n s f e ro fB / I - a c t i v a t e d4 T 1D L N
cells. As shown in Figure 1, CYP treatment alone briefly
slowed tumor progression, but did not lead to complete
tumor regression in any mice. Complete tumor regres-
sion was seen in 6 out of 6 mice treated with CYP plus
adoptive transfer of B/I-activated tumor-sensitized lym-
phocytes. We have previously shown and published that
adoptive transfer of B/I activated 4T1 DLN was ineffec-
tive at inducing tumor regression [28,31].
Figure 1 Adoptive transfer of bryostatin and ionomycin
activated tumor DLN lymphocytes induces regression of 10
day 4T1 tumors. Mice with established 9 day tumors either were
untreated or were treated with CYP (100 mg/kg i.p. on day 9),
alone, or CYP followed by adoptive transfer of 10 × 10
6 4T1 DLN
lymphocytes (on day 10) which had been activated with B/I and
expanded in culture. Mean tumor areas ± SE are charted over time
versus days after tumor inoculation. Treatment with CYP + B/I
activated lymphocytes induced complete tumor regressions in 100%
of the mice. CYP treatment alone slowed tumor growth only
temporarily. Numbers to the right indicate the number of mice with
complete tumor regression per total number of mice in each group.
The CYP + AIT group was significantly different from the Nil and
CYP groups [F(2,17) = 21.8328, P < 0.0001].
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+ cells are the predominant mediators of tumor
regression
We hypothesized that the predominant cells responsible
for tumor regression induced by AIT with B/I-activated
tDLN cells would be in the CD8
+ subset. By immunohis-
tochemistry, we had previously seen CD4
+ and CD8
+
T cells infiltrating tumors in mice treated with B/I acti-
vated lymphocytes [28]. To determine the relative roles
of CD4 and CD8 T cell subsets in inducing tumor regres-
sion, BALB/c mice bearing 4 day tumors and pre-treated
with CYP, underwent AIT using untreated B/I activated
DLN cells, C’-treated cells, anti-CD4 + C’-treated cells,
or anti-CD8 + C’-treated cells. In mice treated with CD8-
depleted cells, 4T1 tumor growth was depressed slightly
compared to CYP alone, but none of the tumors
regressed completely, and tumor sizes were not signifi-
cantly different from CYP alone (Figure 2). In tumor-
bearing mice treated with CD4-depleted DLN, 4T1
tumors regressed completely in 5/6 mice, with a growth
curve that was little different from AIT with untreated or
C’-treated cells.
Host T cells are not required for tumor regression
To confirm our hypothesis that host T cells play little or
no role in tumor regression after adoptive transfer, athy-
mic nude mice with 4 day 4T1 tumors were treated
with CYP alone or CYP + B/I activated 4T1 draining
lymphocytes, with or without exogenous IL-2 (7500 U
i.p. on days 0 - 3 after AIT). Adoptive transfer of B/I
activated tDLN was effective at inducing 4T1 tumor
regression in nude mice pre-treated with CYP but IL-2
was neither beneficial nor required(data not shown,
[F(2,13) = 11.289, P = 0.0014]). This result indicates that
host T cells are neither required for tumor regression.
B/I activated tDLN demonstrate increased expression of
message for cytolytic mediators
We hypothesized that B/I activation and in vitro expan-
sion of tumor draining lymphocytes led to the develop-
ment of highly activated effector T cells, capable of
inducing tumor regression. Activation and expansion of
tDLN lymphocytes with B/I + IL-2 was associated with
increased expression of mRNA for molecules associated
with cytotoxic activity, including granzyme B, perforin,
and Fas ligand, when compared to unactivated tDLN
(Figure 3A).
B/I activated tDLN release IFN-g in response to tumor
challenge
We and others have previously noted a strong correla-
tion between interferon- IFN-g production and tumor
regression in other tumor models [31-37]. BALB/c mice
were either untreated, vaccinated with irradiated 4T1,
treated with CYP alone, or treated with CYP + AIT
with B/I activated 4T1 tDLN lymphocytes. Spleens were
harvested 5 days after adoptive transfer, and pooled
splenocytes from 3 mice in each treatment group were
co-cultured with irradiated 4T1 or unrelated MethA sar-
coma for 24 hours on an IFN-g ELISpot plate. As shown
in Figure 3b, numbers of IFN-g producing cells were
greatest in response to 4T1 in mice treated with CYP +
AIT. A small number of cells in each of the other
groups also produced IFN-g in response to 4T1, which
may be explained by sensitization to 4T1 in these
tumor-bearing hosts. There was no IFN- g response to
Meth A.
B/I activation leads to increased expression of memory
markers by tumor draining lymphocytes
There have recently been reports in the literature that
adoptive transfer of central memory or early effector
phenotype cells (which are CD62L
high)i sm o r ee f f e c t i v e
Figure 2 Therapeutic effect of AIT is mediated predominantly
by CD8
+ T cells. Mice with established 4T1 flank tumors were
either untreated, treated with CYP alone (on day 3) or CYP on day 3
+ AIT on day 4 with 20 × 10
6 cells from culture. The cells infused
for AIT were either untreated, treated with C’ alone, treated with
anti-CD8 Ab + C’ or with anti-CD4 antibody + C’ prior to transfer.
Mean tumor sizes ± SE are charted over time. Numbers to the right
indicate the number of mice with complete tumor regression per
total number of mice in each group. The results with AIT using
untreated, C’ treated, and CD4-depleted cells were significantly
different from the untreated group, the CYP only group, and the
CD8-depleted AIT groups [F(4,24) = 32.45, P < 0.0001].
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or late effector phenotype (CD62L
low ) T cells [38,39].
Over the course of expansion after B/I activation, we
observed upregulation of CD62L by previously CD62L
-
cells; 70% of the adoptively transferred cells in the B/I-
activated cultured tDLN cells were CD62L
+. In addition,
we have previously observed in B/I activated cells mini-
mal levels of cytotoxic activity and high IFN-g produc-
tion, which are also consistent with a central memory/
early effector phenotype. Therefore, we investigated the
hypothesis that activation with B/I could skew the pheno-
type of activated T cells towards a central memory or
early effector phenotype, and that these cells were largely
responsible for their anti-tumor efficacy.
In Table 1, expression of phenotypic markers of mem-
ory T cells before and after B/I activation is shown for
the fraction of tDLN cells that were initially CD62L
-.
4T1 tDLN were separated into their CD62L subsets by
magnetic bead selection. Prior to B/I activation, the
CD62L
- fraction was 93% CD62L
- overall and 81% of
the CD8 cells in that fraction were CD62L
-.A f t e rB / I
activation and expansion, expression of CD62L, CD127,
CD69, and CD27 increased dramatically. These increases
in expression of CD127, CD27, CD69, and CD62L are
consistent with acquisition of a central memory (TCM)
phenotype, but we did not observe significant upregula-
tion of CCR7, another memory marker.
Before and after B/I activation and expansion, anti-tumor
activity resides predominantly in the CD62L
- subset
To test the hypothesis that TCM cells (which should be
CD62L
+) generated after B/I activation are responsible
for the efficacy of these cells at inducing tumor regres-
sion, we separated B/I activated and expanded 4T1
tDLN into CD62L
+ and CD62L
- fractions, using mag-
netic beads. Unsorted, CD62L
+,a n dC D 6 2 L
- cells were
then infused into CYP pre-treated 4T1 tumor bearing
mice (Figure 4). Surprisingly, the CD62L
+ subset did not
induce tumor regression, while the CD62L
- subset was
highly effective.
To characterize not only the ultimate phenotype of anti-
tumor effectors after B/I activation, but also the origin of
the adoptively transferred cells that mediate the anti-
tumor activity, we separated tDLN into CD62L
+ and
CD62L
- fractions, both before and after B/I stimulation
and expansion. Unsorted B/I activated lymphocytes,
CD62L
+ cells that remained CD62L
+ after B/I and expan-
sion (CD62L
+ ® CD62L
+ ), CD62L
+ cells that downregu-
lated CD62L after B/I treatment and expansion (CD62L
+
® CD62L
- ), CD62L
- cells that remained CD62L
- after B/I
Figure 3 Adoptive transfer of B/I activated T cells into CYP
pretreated hosts results in tumor specific production of
interferon-g and other cytotoxic mediators by adoptive host
splenocytes. A) RT-PCR analysis of granzyme B, perforin, FasL and
actin mRNA from murine 4T1 tumor-DLN CD8
+ cells, either fresh or
after activation with B/I and expansion in IL-2. Increased expression
of FasL, perforin, and granzyme B was seen in CD8+ T cells after B/I
activation. This is a representative experiment of 3 replicates. B)
ELIspot assays for IFN-g producing cells from spleens of untreated
4T1 tumor-bearing mice, CYP-treated tumor-bearing mice, tumor
bearing mice treated with CYP + AIT with B/I-activated tDLN, and
4T1 bearing mice immunized with irradiated 4T1 cells. Splenocytes
were unstimulated or stimulated in vitro with 4T1 or Meth A
sarcoma cells. Results are shown for pooled spleens from 3 mice in
each group. Mean values from paired wells are shown. This is a
representative experiment of 5 replicates.
Table 1 Phenotype of CD62L
--enriched T cells from tDLN,
before and after B/I pulse and expansion in IL-2
% of CD8 cells which express: Before B/I After B/I
CD62L
+ 19% 46%
CD127
+ 9% 48%
CD69
+ 45% 90%
CD27
+ 37% 89%
CCR7
+ 46% 42%
4T1 tDLN were harvested and separated by expression of CD62L. Subsets
were activated by B/I and expanded for 7 days. Prior to B/I activation, and
again after expansion, cells were stained for expression of CD8, CD62L, CD127,
CD69, CD27, and CCR7. The CD62L
- fraction was initially 93% CD62L
- overall.
Shown in the table is the percentage of CD8
+ cells which express specific T
cell markers, before and after B/I expansion, in the initially CD62L
- fraction of
tDLN cells. Results are representative of more than three independent
experiments.
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- ®CD62L
- ), or CD62L
-
cells that upregulated CD62L expression after B/I and
expansion (CD62L
- ® CD62L
+ )w e r ei n f u s e di n t oC Y P
pre-treated tumor bearing mice (Figure 5). Prior to B/I
activation, between 75-83% of lymphocytes are CD62L
+
and 17-25% are CD62L
- (pooled data from 4 experiments).
After B/I activation, from the initially CD62L
+ fraction,
87% of the cells remained CD62L
+ and 13% downregu-
lated CD62L. From the initially CD62L
- fraction, 80% of
the cells remained CD62L
- and 20% of the cells upregu-
lated CD62L (Representative data from one experiment of
4). In 4 out of 4 experiments, CD62L
- ®CD62L
- cells
induced complete tumor regression, even when as few as
375,000 cells per mouse were transferred (Figure 5a, 5b).
In 3 out of 4 experiments, CD62L
- ®CD62L
+ cells
induced complete tumor regression(Figure 5a). However,
when B/I activated lymphocyte subsets were used to treat
slightly larger tumors (inoculated at 100,000 cells/mouse,
2x the usual inoculum), CD62L
- ®CD62L
+ cells were not
effective at mediating tumor regression, slowing tumor
growth only slightly (Figure 5b). In contrast, even with the
greater tumor burden, CD62L
- ®CD62L
- cells induced
complete tumor regression in all of the treated mice
(Figure 5b). In all experiments, CD62L
+ ®CD62L
- cells
were incapable of mediating tumor regressions, but with
smaller tumor burdens these cells did delay tumor growth
modestly (Figure 5a). Finally, adoptive transfer of CD62L
+
® CD62L
+ cells was consistently ineffective at inhibiting
tumor growth (Figure 5).
Adoptively transferred cells persist in the tumor-bearing
host, accumulating preferentially in the tumor draining
lymph nodes
By staining B/I activated DLN lymphocytes with CFSE
prior to adoptive transfer, the cells can be “tracked,”
and proliferation of the adoptively transferred cells can
also be measured in the host. At 1 hour, 3, 5, 7, and
12 days after adoptive transfer, we harvested the
spleens, lungs, inguinal tDLN, and contralateral lymph
node (cLN) from AIT-treated mice. The proportion of
CFSE+ cells in the spleen peaked on day 3 at 10.5%
of the total splenocytes and then declined rapidly
(Table 2). Only a small proportion of CFSE
+ cells were
f o u n di nt u m o r so nd a y3 ,b u ti n c r e a s e dt oam a x i -
mum of 2% by day 5; CFSE
+ cell proportions declined
thereafter.
CFSE+ cells in tDLN were 9% of the cells by day 3
and persisted at that level at least until day 12. CFSE
+ T
cells were seen in the tDLN up to 28 days (2.7%) after
AIT (latest date tested, data not shown). Although,
CFSE
+ cells were 6 to 8% of cells in the contralateral
lymph node between days 3 and 12 after AIT, the total
number of lymphoid cells in the cDLN was much lower
than in the tDLN at all times examined. Thus, the total
number of CFSE
+ cells in the tDLN was up to 170-fold
higher than in the cDLN (Table 3). This suggests that
the increased numbers of adoptively transferred cells in
t h et D L Nl i k e l yr e s u l t sf r o ms e l e c t i v et r a f f i c k i n ga n d / o r
increased proliferation.
Figure 4 CD62L phenotype (after B/I activation and expansion) of T cells mediating tumor regression. Mice with established 4T1 flank
tumors were either untreated, treated with CYP alone (100 mg/kg i.p. on day 3) or CYP + AIT (on day 4) with 10 × 10
6 unsorted, CD62L
+ or
CD62
- B/I activated tumor-sensitized lymphocytes. CD62L separation was performed after B/I activation and expansion for 7 days in culture, just
prior to adoptive transfer. Mean tumor sizes ± SE are charted over time. Numbers to the right indicate the number of mice with complete
tumor regression per total number of mice in each group. The AIT and CD62L
- AIT groups were significantly different from the untreated group
and the CD62L
+ AIT groups [F(4,29) = 15.3889, P < 0.0001].
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assessed T cell infiltration in tumors by immunohisto-
chemistry. We observed that tumors from mice treated
with AIT using vDLN cells showed infiltration of CD8+
T cells (16-50%) on day 1 after AIT and CD8+ cells per-
sisted at levels under 15% until the last time point
checked (day 11). We did not observe infiltration of
untreated or CYP treated tumors by CD8+ T cells at
any of the time points (data shown in table 4). CD4
infiltrate was seen in all tumor bearing mice, with
greater percentages of CD4 infiltrate seen in AIT + CYP
treated tumors, as compared to untreated or CYP trea-
ted hosts (data not shown).
The trafficking and/or proliferation of adoptively
transferred cells in the host is tumor specific
To determine whether the selective accumulation of
adoptively transferred cells in the lymphoid organs of
adoptive hosts was antigen specific or resulted from
non-specific changes caused by growth of a tumor, B/I
activated lymphocytes labeled with CFSE were infused
into normal mice, 4T1-bearing hosts, and MethA
Figure 5 Anti-tumor activity resides predominantly in the subset of tDLN cells that were initially CD62L
- and remained CD62L
- after B/
I activation and expansion in culture. Tumor-sensitized lymphocytes were separated by CD62L phenotype, both before and after B/I
activation, resulting in 5 groups: unsorted B/I activated tDLN, CD62L
+ cells that remained CD62L
+ after B/I activation and expansion (CD62L
+ ®
CD62L
+ ), CD62L
+ cells that downregulated CD62L after B/I (CD62L
+ ® CD62L
- ), CD62L
- cells that remained CD62L
- after B/I (CD62L
- ®CD62L
- ),
and CD62L
- cells that upregulated CD62L expression after B/I (CD62L
- ® CD62L
+ ). Mean tumor sizes ± SE are charted over time. Numbers to
the right indicate the number of mice with complete tumor regression per total number of mice. A) 4T1 tumor-bearing mice (3 days after
inoculation of 50,000 4T1 cells) were either untreated, treated with CYP alone or treated with CYP + AIT (on day 4) with unfractionated or twice
fractionated cells, as described above. 20 × 10
6 whole, 20 × 10
6 (CD62L
+ ® CD62L
-), 4 × 10
6 (CD62L
- ® CD62L
+), or 8 × 10
6 (CD62L
- ® CD62L
-
) cells were transferred, variations due to the limited number of cells available in subsets. The unseparated, (CD62L
- ® CD62L
+), and (CD62L
- ®
CD62L
- ) groups were significantly different from the untreated, CYP only, and (CD62L
+ ® CD62L
-) groups [F(5,32) = 22.9156, P < 0.0001]. B) 4T1
tumor-bearing mice (3 days after inoculation of 100,000 4T1 cells) were either untreated, treated with CYP alone or treated with CYP + AIT (on
day 4) with 15 × 10
6 unfractionated or twice fractionated cells (except for the (CD62L
- ® CD62L
+) group, which received 10 × 10
6 cells). The
unseparated and (CD62L
- ® CD62L
- ) groups were significantly different from the untreated, CYP only, (CD62L
- ® CD62L
+ ), and (CD62L
+ ®
CD62L
- ) groups [F(6,37) = 17.7496, P < 0.0001].
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Page 7 of 16sarcoma bearing-hosts. In the absence of 4T1 tumor
antigen, accumulation and/or proliferation of adoptively
transferred cells was greatly reduced. On day 3, 10.4% of
the splenocytes in 4T1 bearing hosts were CFSE
+,c o m -
pared to only 2.1% in MethA bearing hosts and 2.4% in
naïve hosts. On day 6, 3.3% of the splenocytes in a 4T1
bearing host were CFSE
+, but only 0.5% were CFSE
+ in
a MethA bearing host. Similar results were seen in the
tDLN; 9.2% of 4T1 tDLN were CFSE
+ on day 3 and
10.1% on day 6. In MethA tDLN, only 3.1% of the cells
were CFSE
+ on day 3, declining to 2% on day 6 (data
summarized in Table 5).
Adoptively transferred cells have an activated phenotype
in the tumor bearing host (TBH)
In order to determine the phenotypes of the adoptively
transferred cells accumulating in the recipient tDLN
after AIT with B/I-activated lymphocytes, tDLN were
harvested from 4T1 TBH mice at varying times after
CYP + AIT with CFSE-labelled B/I-activated lympho-
cytes. On day 3, 27.6% of CFSE
+ cells in the tDLN were
CD8
+,7 0 . 3 %w e r eC D 4
+, and 0.3% were DX5
+ (Figure
6a). More than 95% of the CFSE
+ cells in the tDLN
were CD44
+ on days 3, 6, and 10. Between 76% and
80% of the CFSE
+ cells in the tDLN were CD62L
+,a n d
46.5-48.6% of the adoptively transferred cells in the
tDLN were CD69
+. As shown in Figure 6b, three to four
distinct generations of CFSE
+ cells became evident as
time progressed.
Adoptively transferred cells proliferate in the tumor
bearing host, with more generations seen in the tumor
draining lymph nodes than in the contrateral nodes
With the use of Modfit analysis software, it is possible
to determine the number of cycles of proliferation
occurring in CFSE labeled cells, and the percentage of
cells in each generation. As shown in Figure 7, greater
proliferation of the adoptively transferred cells was seen
in tDLN, with higher percentages of cells in later gen-
erations than in cLN on days 3 and 6 after adoptive
transfer. On day 3, 30.42% of the adoptively transferred
cells in tDLN were in generations 5 and above, com-
pared to just 19.74% of cells in the cLN. The difference
Table 3 Absolute numbers of adoptively transferred cells
in lymph nodes of tumor-bearing mice
Day 3 Day 5 Day 7 Day 10
tDLN 4.6 × 10
5 3.9 × 10
5 2.8 × 10
5 2.1 × 10
5
cLN 9.1 × 10
4 2.3 × 10
3 1.8 × 10
4 6.4 × 10
4
Mice with established 4T1 flank tumors were either untreated, treated with
CYP alone on day 9, or were treated with CYP on Day 9 after tumor
inoculation followed by AIT with 50 × 10
6 CFSE-stained B/I activated 4T1 tDLN
(on day 10). At 1 hour, 3, 5, 7, and 10 days after AIT, the tDLN and
contralateral LN (cLN) were harvested and analyzed by flow cytometry for
CFSE
+ cells. This is a representative experiment of 5 replicates. Absolute
numbers of cells found in each tissue are listed.
Table 2 In vivo trafficking and accumulation over time of
adoptively transferred cells in tumor-bearing mice
tDLN cLN Tumor Spleen
Day 0 0.7% 0.7% 0.1% 3.0%
Day 3 9.2% 5.9% 0.2% 10.5%
Day 5 10.1% 7.3% 2.1% 3.1%
Day 7 10.3% 6.5% 0.8% 3.4%
Day 12 8.4% 8.7% 0.1% 2.1%
Mice with established 4T1 flank tumors were either untreated, treated with
CYP alone on day 9, or were treated with CYP on Day 9 followed by AIT with
50 × 10
6 CFSE-stained B/I activated 4T1 tDLN (on day 10). At 1 hour, 3, 5, 7,
and 12 days after AIT, the tumors, spleens, tDLN, and contralateral LN (cLN)
were harvested and analyzed by flow cytometry for CFSE
+ cells. This is a
representative experiment of 5 replicates. Percentages of CFSE
+ cells found in
different tissues at various times after AIT ("0” is 1 hour after infusion of cells)
are shown.
Table 4 CD8+ T cells infiltrate 4T1 tumors after AIT
treatment
Group Nil CD4 CD8a
Day 1: Control - + -
Cyp - _ -
AIT/CYP - ++ ++
Day 4: Control - + -
CYP - ++ -
AIT/CYP - +++ +
Day 7: Control - + -
CYP - + -
AIT/CYP - ++
Day 11: Control - ++ -
CYP - + -
AIT/CYP - +++ +
Grading:
- No stain
+1 - 1 5 %
++ 16-50%
+++ >50%
Mice with established 4T1 flank tumors were either untreated, treated with
CYP alone on day 3, or were treated with CYP on Day 3 after tumor
inoculation followed by AIT with 25 × 10
6 B/I activated 4T1 tDLN (on day 4).
At 1, 4, 7 and 11 days after AIT, the tumors were harvested and tumor cross-
sections were stained for CD4 and CD8 expression. A representative
experiment is shown.
Table 5 B/I activated tDLN track preferentially to 4T1
tDLN and persist
Tumor MethA 4T1 No Tumor
Day 3 Spleen 2.1% 10.4% 2.4%
Day 6 Spleen 0.5% 3.3% 1.7%
Day 3 tDLN 3.1% 9.2% _____
Day 6 tDLN 2% 10.1% _____
Naïve mice or mice with established MethA or 4T1 flank tumors were treated
with CYP on day 9 followed by AIT with 50 × 10
6 CFSE-stained B/I activated
4T1 tDLN (on day 10). At 3 and 6 days after AIT, the tDLN and spleens were
harvested and analyzed by flow cytometry for CFSE + cells. This is a
representative experiment of 3 replicates.
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Page 8 of 16Figure 6 Phenotype of adoptively transferred cells after infusion into TBH mice . Mice with established 4T1 flank tumors received CYP (100
mg/kg i.p.) on day 9 after tumor inoculation, followed by AIT with 50 × 10
6 B/I activated CFSE-stained lymphocytes on day 10. At days 3, 6 and
10 after AIT, the tDLN were harvested, stained for expression of cell surface markers, and analyzed by flow cytometry. Results shown are gated
for CFSE
+ cells. A) Dual color analysis of CFSE and CD8 or CD4 or DX5 on Day 3. B) Dual color analysis of CFSE and CD44, CD62L or CD69 on
days 3, 6 and 10 after AIT.
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Page 9 of 16was not as striking on day 6 (67.8 vs. 63.4%, data not
shown), but, as shown below, the proliferation is not
just dependent on antigen but also may result from the
prior stimulation with B/I in vitro.
Proliferation in vivo was dependent upon B/I activation
before adoptive transfer
To ascertain whether the proliferation we observed
in vivo for B/I activated tDLN in TBH mice resulted sim-
ply from homeostatic proliferation after the CYP treat-
ment or is enhanced by the prior B/I stimulation, freshly
harvested tDLN were transferred into CYP pre-treated
TBH mice and B/I activated tDLN were infused into
similar hosts, with or without CYP pre-treatment. As
shown in Figure 8, adoptively transferred non-activated
tDLN did not proliferate significantly, even in mice bear-
ing the relevant tumor and treated with CYP. These cells
also did not induce tumor regression (data not shown).
In contrast, strong proliferation was seen in B/I activated
tDLN transferred into TBH, with or without CYP pre-
treatment (Figure 8). Thus, the proliferation of adoptively
transferred cells in TBH mice was induced neither by
CYP pre-treatment of the host before AIT nor by stimu-
lation with tumor antigen, but required B/I activation.
How does CYP augment the anti-tumor effect of AIT with
B/I-activated lymphocytes?
We observed slightly greater proliferation of adoptively
transferred CFSE-labelled cells in the tDLN of CYP pre-
treated hosts compared to similar hosts not treated with
CYP. In CYP pretreated hosts, 9.38% of cells were in
generation 6 and 5.26% of cells in generation 7 on day
3, versus 6.63% in generation 6 and 2.5% in generation 7
in mice not treated with CYP. The numbers of adoptively
transferred cells in the tDLN of CYP-treated or untreated
hosts were roughly similar on days 3 and 7 after adoptive
transfer. The number of CFSE
+ cells declined by day 10
in the tDLN of un-treated hosts (5 × 10
4 cells vs 3 × 10
5
cells in CYP pre-treated hosts). CYP pretreatment, there-
fore, modestly enhanced the proliferation of adoptively
transferred cells and the persistence of these cells at later
time points in the tDLN.
In order to determine whether CYP pre-treatment
altered the functional response or number of responsive
T cells after AIT, the number of cells capable of produ-
cing IFN-g in response to 4T1 tumor in spleens har-
vested from untreated TBH mice, or TBH mice treated
with AIT, with or without CYP pre-treatment, was
assessed. As shown in Figure 9A and 9B, the greatest
number of cells producing IFN-g in response to 4T1
tumor was seen in spleens of mice who received CYP
prior to adoptive transfer of B/I activated cells.
Discussion
In this and previous studies, we have demonstrated that
B/I activation of tDLN cells produces a population of
cells with potent anti-tumor activity against established
tumors up to 10 days after inoculation. Even tDLN har-
vested from donors 20 days post-tumor inoculation, from
a metastatic disease state and possibly immunosuppres-
sive milieu, are capable of inducing tumor regression
after B/I activation and adoptive transfer into tumor
bearing hosts. 14 days after tumor inoculation, 80% of
4T1-tumor bearing mice have measurable metastatic dis-
ease, and by 18 days, 100% have lung metastases [31].
We had previously shown that B/I preferentially activated
Figure 7 Adoptively transferred B/I-activated cells proliferate in vivo. Mice with established 4T1 flank tumors were treated with CYP on day
9 after tumor inoculation followed by AIT with 50 × 10
6 CFSE-stained B/I activated lymphocytes from culture (on day 10). At 3 days after AIT,
the tDLN, and contralateral LN (cLN) were harvested and analyzed by flow cytometry for CFSE
+ cells. Proliferation and generations of CFSE
+ cells
were analyzed with ModFit software. Modfit analysis showed the presence of at least 9 cell generations (Reduced chi-squared = 1.238).
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Page 10 of 16a subset of tDLN cells that were initially CD62L
- and that
these cells accounted for all of the subsequently devel-
oped anti-tumor activity [28]. In the present studies, we
have further characterized the post-activation phenotype
and the in vivo trafficking, and proliferation of the anti-
tumor effector cells generated by B/I activation and
expansion in culture. The most potent anti-tumor effec-
tor cells were highly activated CD8
+ T cells which
remained CD62L
- after B/I activation and expansion.
These cells also respond to tumor antigen by specific
release of IFN-g, which we and others have shown corre-
lates with anti-tumor activity [31-37].
Recently, there have been a number of reports that
either central memory and/or early effector T cells are
the most effective cell types for AIT [38,39]. Conversion
of adoptively transferred cells to the central memory
phenotype has also been observed in adoptive hosts
[40]. TCM cells or early effector cells, as opposed to fully
differentiated effector or effector memory (TEM) cells,
have been found to have a greater ability to home to
lymphoid tissue via expression of CD62L and CCR7,
produce IL-2, proliferate more rapidly in response to
antigen and cytokines, and then differentiate into effec-
tor cells [41-43]. TEM cells lack lymph node homing
receptors, exhibit direct (ex vivo) cytotoxic activity, do
not produce IL-2, and are found in non-lymphoid tis-
sues [44-46]. Thus, TCM cells, despite a lower level of
i m m e d i a t ee f f e c t o rf u n c t i o n s ,m a yb em o r ee f f e c t i v ef o r
AIT, because they produce a larger number of anti-
tumor cells for a longer period of time. As T cells are
repeatedly stimulated, they differentiate from early effec-
tor to effector to late effector memory cells. They also
downregulate receptors for homeostatic cytokines, and
upregulate pro-apoptotic molecules.
We found that after 18 hour B/I activation and 7 days
of expansion in IL-2, the initially CD62L
- effector cell
population harvested from donor mice had largely up-
regulated the expression of CD62L (up to 68% CD62L
+ ).
We also observed up-regulation of memory markers
CD27, CD44, CD69, and CD127. Furthermore, 76.4% of
the adoptively transferred cells that were isolated from
the adoptive hosts’ tDLN 3 days after AIT were CD62L
+,
Figure 8 B/I activation is required for proliferation of adoptively transferred tDLN. Mice with established 10 day 4T1 flank tumors received
50 × 10
6 CFSE-stained lymphocytes, which were either activated with B/I and expanded in culture or untreated ("No B/I”). The mice shown in
the upper panel received AIT with cells only; mice in the lower 2 panels received CYP (100 mg/kg i.p.) on day 9 after tumor inoculation. At days
3, 5, 7 and 10 after AIT, the tDLN were harvested from the recipient mice and analyzed by flow cytometry for CFSE
+ cells. This is a representative
experiment of 3 replicates.
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Page 11 of 16Figure 9 CYP treatment of AIT recipients increases the number of lymphocytes which produce IFN-g in response to 4T1 tumor cells.A )
ELIspot assays for IFN-g producing cells from spleens of mice with established 10 day 4T1 flank tumors which were either untreated, or received
AIT with 50 × 10
6 B/I activated lymphocytes, with or without CYP pre-treatment (100 mg/kg IP) on day 9. Splenocytes harvested from recipient
mice 5 days after AIT were stimulated with 4T1 or MethA sarcoma cells and the number of cells producing IFN-g were enumerated. Results are
pooled from 3 mice in each group, mean values from paired wells are shown, and are representative of 3 replicate experiments B) ELIspot assays
for IFN-g producing cells from spleens of mice with established 10 day 4T1 flank tumors which were either untreated, received AIT with 50 × 10
6
B/I activated lymphocytes, with or without CYP pre-treatment (100 mg/kg IP) on day 9, immunized with irradiated 4T1 cells with or without CYP
pre-treatment(100 mg/kg IP) on day 9. Splenocytes harvested from recipient mice 8 days after AIT were stimulated with 4T1 or MethA sarcoma
cells and the number of cells producing IFN-g were enumerated. Results are pooled from 3 mice in each group, mean values from paired wells
are shown, and are representative of 3 replicate experiments.
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Page 12 of 16which suggested that activation with B/I may stimulate
sensitized or CD62L
- TEM (CD62L
- CCR7
low,C D 2 7
+,
BCL-2
hi) or effector T cells to shift to a CD62L
+ TCM
phenotype, which we initially supposed would be largely
responsible for the anti-tumor effects we have observed.
However, we found instead that adoptive transfer of
B/I activated and expanded CD62L
- cells (separated
after expansion in culture) were most effective at med-
iating tumor regression, and that the CD62L
+ fraction
had little or no anti-tumor activity. There are a few
explanations for these somewhat unexpected results and
how it differs from previous reports. For example, this
result may reflect enrichment of tumor antigen specific
Treg cells in the CD62L
+ subset, as recently reported
[47]. Alternatively, the CD62L
- cells present after B/I
activation and expansion may be analogous to secondary
response derived memory cells, which are CD62L
- [48].
Recent literature suggests a distinct phenotype for T
memory cells derived from primary versus those from
secondary immune responses [45] [48-52]. CD8 T cells
undergoing a secondary response expand more rapidly
and divide at a faster rate than in a primary response
[53]. In the Listeria monocytogenes (LM), Lymphocytic
Choriomeningitis Virus (LCMV), and TcR transgenic
models, it has been found that secondary immune
responses produced memory CD8 T cells which are
slow to convert to TCM, as measured by both CD62L
expression and antigen induced IL-2 production [51].
Primary and secondary response memory CD8 T cells
have equal proliferative capacities in respect to numbers
of generations, but secondary memory CD8 T cells
remain CD62L
low, in contrast to the CD62L
high memory
CD8 cells resulting from primary responses. Moreover,
secondary CD62L
low memory cells are more effective
against virulent LM infection and have increased cytoly-
tic activity [48]. The CD62L
- T cells harvested from cul-
ture after B/I activation and expansion may be more
analogous to memory cells derived from a secondary
response, which our protocol mimics by re-activation of
antigen-sensitized T cells with B/I. This contrasts with
the TEM or TCM cells generated by stimulating naïve
pmel-1 TcR transgenic T cells with antigen and cyto-
kines in vitro [38,39]. These approaches would generate
TCM CD8 cells of the primary type, with the secondary
immune response not occurring until after adoptive
transfer into the tumor bearing host and subsequent in
vivo vaccination with fowlpox vaccine encoding hgp100
[38,39]. In our model, the primary immune response
occurs in vivo in the tDLNs of the donor mice, and the
s e c o n d a r yi m m u n er e s p o n s eo c c u r sin vitro upon B/I
activation of the tDLN. Our model may be more anala-
gous with the clinical situation, in which sensitized
PBMCs, tDLN, or vDLN are isolated from cancer
patients, activated and expanded in vitro, and secondary
memory T cells are then adoptively transferred into
patients. Thus, B/I may have the advantage of generat-
ing secondary type T memory cells for adoptive transfer.
To further characterize the nature of the anti-tumor
effector cells and their CD62L phenotype, tDLN lym-
phocytes were separated by CD62L phenotype both
before and after B/I expansion. The most potent anti-
tumor cells were the (CD62L
- ®CD62L
- ) cells, which
were capable of inducing tumor regression when as few
as 375,000 B/I activated cells were transferred and even
when double the normal tumor cell inoculum was used
to establish the tumors. Studies with CFSE labeled cells
showed that the adoptively transferred (CD62L
-
®CD62L
- ) subset, despite the lack of CD62L, were able
to traffic to tDLN after adoptive transfer, proliferated
extensively in the adoptive hosts, and maintained their
lack of CD62L expression (data not shown). H The
(CD62L
- ®CD62L
+ ) subset was less effective than
(CD62L
- ®CD62L
- ) cells at inducing tumor regression,
especially at higher tumor inocula. Surprisingly, (CD62L
+ ®CD62L
- ) cells were capable of delaying tumor pro-
gression. We previously had not seen any evidence of
anti-tumor activity from initially CD62L
+ subsets. These
(CD62L
+ ®CD62L
- ) cells may be tumor specific early
effector or memory cells when harvested from donor
mice and then may acquire an effector phenotype after
exposure to B/I. The existence of these cells may have
been masked in previous experiments in which separa-
tions were done either before or after B/I activation.
When the CD62L separation was carried out only before
B/I activation and expansion, they would have been
vastly outnumbered by the ineffective (CD62L
+
®CD62L
+ ) subset and possibly suppressed by any Treg
(CD4
+ CD25
+) cells also present in that fraction. When
CD62L separation was carried out only after B/I activa-
tion and expansion, these cells would have been in the
CD62L
- subset. We have repeated these experiments
with similar results, in both the B16 melanoma and
B16-OVA models, indicating that this is not a tumor
model specific result (data not shown).
Adoptively transferred cells were shown to persist
and/or proliferate preferentially in hosts bearing the
relevant tumor and accumulated preferentially in tumor
draining lymph nodes. The decline in adoptively trans-
ferred cells in the spleens after day 3 is consistent with
trafficking of these cells to sites of tumor antigen con-
centration. The low number of CFSE
+ cells seen in the
tumors may reflect proliferation of the cells beyond the
limits of dye detection; after generation 10-12, CFSE
becomes too dilute to be readily detected. Using immu-
nohistochemical staining of tumors (not shown), both
CD4
+ and CD8
+ cells were observed to infiltrate into
tumors, although CD4
+ cells do not appear to be
required for tumor regression. Although some of these
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Page 13 of 16infiltrating cells could be of host origin, we have found
that AIT is effective in nude mice [not shown and [31]],
suggesting that host T cells are also not required.
In our model, the increased numbers of adoptively
transferred cells in the tDLN suggest that specific
uptake and/or proliferation of lymphocytes occurred at
the site of antigen and antigen-presenting cells. How-
ever, it is not possible to tell how much of the difference
in the numbers of cells at the tDLN vs the cLN is due
to specific trafficking and accumulation at the site of the
tDLN and how much is due to increased proliferation in
the tDLN. In fact, we did also observe increased prolif-
eration of the adoptively transferred cells in the tDLN
as compared to the cLN, especially on day 3. However,
in the absence of specific tumor antigen, adoptively
transferred cells did not persist in the host LN. Thus,
accumulation of adoptively transferred lymphocytes in
the tDLN seems to be specific for tumor antigen, and
not merely a result of non-specific inflammation.
In contrast to our trafficking results, others have
reported that trafficking and accumulation of infused T
cells in TBH mice was indiscriminate, without preference
for tumor-draining LN versus other LN [38,39]. It is
important to note, however, that after infusion of T cells
in those experiments, the adoptive hosts received sys-
temic antigen, in the form of a recombinant fowlpox vac-
cine, as well as exogenous cytokines. Both of these would
be expected to result in stimulation and proliferation of
the adoptively transferred cells throughout the adoptive
host [38,39]. Furthermore, the TcR transgenic T cells
that were infused in that model recognize a self antigen
that would be expected to be present throughout the
host, not only at the site of tumor growth or the tDLN.
In our model, proliferation of the adoptively trans-
ferred cells in the host was also dependent upon prior
B/I activation; we did not observe proliferation of unac-
tivated tDLN lymphocytes after adoptive transfer, even
in CYP-pretreated hosts. Thus, the proliferation seen in
our protocol is a result of B/I activation, and not merely
homeostatic proliferation. One of the key potential
advantages of B/I activation of tDLN is the ability of
these cells to continue proliferating in adoptive hosts
after AIT, without the need for exogenous cytokines or
antigen vaccination. Interestingly, at the time these cells
are harvested from culture, proliferation in vitro is gen-
erally declining, but apparently accelerates again in vivo.
In previous studies, we have shown that adoptively
transferred B/I activated lymphocytes were more effective
at inducing tumor regression in combination with CYP
pre-treatment. The effectiveness of B/I activated lympho-
cytes with CYP pre-treatment and the lack of require-
ment for exogenous cytokine therapy is a major
advantage of our method of activating tDLN. Several dif-
ferent mechanisms may account for CYP mediated
modulation of the immune system. Several studies sug-
gest that CYP causes a breakdown of regulatory mechan-
isms by removal of a suppressor cell population [54-58].
In early studies, mice that were pre-treated with CYP 2-3
days in advance of sensitization exhibited enhanced con-
tact sensitivity or delayed type hypersensitivity [58-60].
Recent data suggest that CYP may selectively inhibit or
deplete CD4+ CD25+ Treg cells [61-65]. CYP may also
enhance AIT by temporarily inhibiting tumor growth, by
creating “space” for T cell growth, or by a relative
increase in cytokines that stimulate T cell proliferation
[66].
As noted earlier, in the absence of B/I activation, adop-
tively transferred cells did not proliferate in CYP pre-
treated hosts, indicating that CYP alone does not lead to
homeostatic proliferation of adoptively transferred cells
and that B/I activation was required for the proliferation
of these cells in vivo. B/I activated lymphocytes, on the
other hand, proliferated in the adoptive hosts with or
without CYP pre-treatment. Arguably, slightly more pro-
liferation was seen in CYP pre-treated hosts, but what
was more striking was the increase in tumor antigen spe-
cific IFN-g-producing cells in CYP pre-treated hosts
compared to untreated hosts. Pre-treatment with CYP
before AIT, it would appear, increases the resulting num-
ber of IFN-g producing cells, possibly from the increase
in availability of homeostatic cytokines or the removal of
suppressive Treg populations.
Conclusions
B/I activation of tDLN generates large numbers of
potent anti-tumor effector tells, as demonstrated by
tumor regression in vivo and production of IFN-g in
vitro. These cells have the ability to traffic to the tumor
draining lymph nodes, to proliferate extensively in vivo
and to mediate tumor regression. Pre-treatment with
CYP enhances the efficacy of adoptive immunotherapy,
by increasing the number of resulting IFN-g producing
cells. The predominant mediators of anti-tumor activity
are CD8
+ T cells which are intially CD62L
- when har-
vested from tDLN donors and remain CD62L
- after B/I
activation and expansion.
The results reported here will be used to distinguish
more precisely the most effective anti-tumor populations
in the tDLN and to explore methods of generating more
of these cells. B/I activationi su n i q u ei nt h a ti ti sc a p -
able of selectively activating only sensitized T cells,
appears to generate highly effective T cells of a second-
ary memory phenotype, and perhaps for that reason,
does not require exogenous cytokines to be adminis-
tered to the adoptive tumor-bearing host. This could
avoid much of the toxicity associated with some AIT
regimens. We are currently exploring the use of alter-
nate g-chain cytokines instead of IL-2 to program even
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Page 14 of 16more effectively the phenotypic development of B/I acti-
vated tDLN to a T memory phenotype, while decreasing
the potential for expanding Treg cells.
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